Cargando…

Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR

INTRODUCTION: Patients with hereditary transthyretin amyloidosis associated with polyneuropathy (ATTRv-PN) experience deterioration in health-related quality of life (HRQOL) as the disease progresses. Findings from the randomized placebo-controlled phase III NEURO-TTR study showed treatment benefit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yarlas, Aaron, Lovley, Andrew, McCausland, Kristen, Brown, Duncan, Vera-Llonch, Montserrat, Conceição, Isabel, Karam, Chafic, Khella, Sami, Obici, Laura, Waddington-Cruz, Márcia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571454/ https://www.ncbi.nlm.nih.gov/pubmed/34355354 http://dx.doi.org/10.1007/s40120-021-00268-x

Ejemplares similares

The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
por: Yarlas, Aaron, et al.
Publicado: (2023)

Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study
por: Yarlas, Aaron, et al.
Publicado: (2021)

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2019)

Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis
por: Dyck, P. James B., et al.
Publicado: (2020)

Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
por: Brannagan, Thomas H., et al.
Publicado: (2022)

Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis
por: Lin, Xiaochen, et al.
Publicado: (2021)

Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial
por: Brannagan, T. H., et al.
Publicado: (2020)

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
por: Mathew, Veena, et al.
Publicado: (2019)

Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen
por: Coelho, Teresa, et al.
Publicado: (2022)

Burden of hereditary transthyretin amyloidosis on quality of life
por: Yarlas, Aaron, et al.
Publicado: (2019)

Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis
por: Gales, Luís
Publicado: (2019)

Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L(Rx) (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2021)

mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis
por: Dyck, P. James B., et al.
Publicado: (2020)

Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
por: Yu, Rosie Z., et al.
Publicado: (2020)

Real‐life experience with inotersen in hereditary transthyretin amyloidosis with late‐onset phenotype: Data from an early‐access program in Italy
por: Luigetti, Marco, et al.
Publicado: (2022)

Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis
por: Obici, Laura, et al.
Publicado: (2019)

Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
por: Vélez-Santamaría, Valentina, et al.
Publicado: (2022)

Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy
por: Cortese, Andrea, et al.
Publicado: (2017)

Transthyretin familial amyloid polyneuropathy (TTR‐FAP): Parameters for early diagnosis
por: Escolano‐Lozano, Fabiola, et al.
Publicado: (2017)

Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP
por: Parman, Yesim, et al.
Publicado: (2016)

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
por: Obici, Laura, et al.
Publicado: (2023)

Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy
por: Gasparotti, Roberto, et al.
Publicado: (2023)

Guideline of transthyretin-related hereditary amyloidosis for clinicians
por: Ando, Yukio, et al.
Publicado: (2013)

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2020)

The Transthyretin/Oleuropein Aglycone Complex: A New Tool against TTR Amyloidosis
por: Bemporad, Francesco, et al.
Publicado: (2022)

Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study
por: Inês, Mónica, et al.
Publicado: (2020)

The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis
por: Vera-Llonch, Montserrat, et al.
Publicado: (2021)

Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology
por: Skrahina, Volha, et al.
Publicado: (2021)

Uptake of Aggregating Transthyretin by Fat Body in a Drosophila Model for TTR-Associated Amyloidosis
por: Pokrzywa, Malgorzata, et al.
Publicado: (2010)

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H.‐J., et al.
Publicado: (2016)

Diflunisal compassive use in transthyretin familial amyloidotic polyneuropathy (TTR-FAP): report of the first Spanish experience
por: Contesse, Sebastián E Azorín, et al.
Publicado: (2015)

“Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy
por: Conceição, Isabel, et al.
Publicado: (2016)

The phenotypical expression of an European inherited TTR amyloidosis in Brazil
por: Cruz, Márcia Waddington, et al.
Publicado: (2015)

Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Waddington‐Cruz, Márcia, et al.
Publicado: (2021)

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2020)

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
por: Dixon, Stacy, et al.
Publicado: (2023)

Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness
por: Nativi-Nicolau, Jose N., et al.
Publicado: (2021)

Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study
por: Vegezzi, Elisa, et al.
Publicado: (2022)

Autosomal-dominant transthyretin (TTR)-related amyloidosis is not a frequent CMT2 neuropathy “in disguise”
por: Grandis, Marina, et al.
Publicado: (2018)

Structural Stabilization of Human Transthyretin by Centella asiatica (L.) Urban Extract: Implications for TTR Amyloidosis
por: Eze, Fredrick Nwude, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u9hl7bsfbslkefu8d7ciu7onr0